Reditux 500mg

Reditux is a medication used to treat certain types of cancer, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It is an injectable medication that works by targeting and destroying certain types of cancer cells.

Composition:

Reditux contains Rituximab, a medication that is a chimeric monoclonal antibody.

Indications:

Reditux is indicated for the treatment of:

1. Non-Hodgkin’s lymphoma (NHL) in combination with chemotherapy
2. Chronic lymphocytic leukemia (CLL) in combination with chemotherapy
3. Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in combination with glucocorticoids

Mechanism of Action:

Rituximab works by:

1. Binding to the surface of certain types of cancer cells, such as B cells and T cells
2. Marking the cancer cells for destruction by the immune system
3. Inhibiting the production of certain proteins that promote cancer growth and survival

Dosage and Administration:

The recommended dosage of Reditux is:

• 500mg administered as an intravenous infusion over 60-90 minutes
• The dose should be adjusted based on the patient’s response to treatment and tolerability

Side Effects:

Common side effects of Reditux include:

1. Infusion reactions (such as fever, chills, and nausea)
2. Fatigue
3. Headache
4. Dizziness
5. Nausea and vomiting
6. Skin rash
7. Increased risk of infections

Serious side effects can include:

1. Hepatitis B reactivation (HBV)
2. Progressive multifocal leukoencephalopathy (PML)
3. Severe allergic reactions
4. Anaphylaxis
5. Hemolytic uremic syndrome (HUS)

Contraindications:

Reditux is contraindicated in patients with:

1. Hypersensitivity to Rituximab or other monoclonal antibodies
2. Active severe infections
3. Severe liver disease
4. Severe kidney disease

Precautions:

1. Patients with a history of cardiovascular disease should be closely monitored while receiving Reditux.
2. Patients with a history of liver disease should be closely monitored while receiving Reditux.
3. Patients with a history of kidney disease should be closely monitored while receiving Reditux.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of infusion reactions or allergic reactions.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.